THE "NEW" PROSTATE CANCER INFOLINK

According to a media release issued on Thursday this week by Molecular Insight Pharmaceuticals, Inc. (MIP), an investigational imaging agent known as Trofex™ (a.k.a, ¹²³I-MIP-1072) may offer a new opportunity to identify the presence of early signs of metastatic prostate cancer in the prostate bed, soft tissues, and bone within 4 hours after injection. … READ MORE …

Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: 123I-MIP-1072, agent, imaging, PMSA, Trofex | 2 Comments »